Recombinant Rhesus Siglec-2/CD22 Protein

• Description:

  Recombinant Rhesus Siglec-2/CD22 Protein _x000D_ Catalog number: B2019242_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 50 µg_x000D_ Molecular Weight or Concentration: 76.5 kDa_x000D_ Supplied as: Powder_x000D_ Applications: a molecular tool for various biochemical applications_x000D_ Storage: -20°C_x000D_ Keywords: Recombinant Rhesus Siglec-2/CD22 Protein (His Tag)_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ References:_x000D_ 1: Fujino Y, Li Q, Chung H, Hikita N, Nussenblatt RB, Gery I, Chan CC. Immunopathology of experimental autoimmune uveoretinitis in primates Autoimmunity. 1992;13(4):303-9._x000D_ 2: Li JL, Shen GL, Ghetie MA, May RD, Till M, Ghetie V, Uhr JW, Janossy G, Thorpe PE, Amlot P, et al. The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies Cell Immunol. 1989 Jan;118(1):85-99._x000D_ 3: Prescher H, Schweizer A, Frank M, Kuhfeldt E, Ring J, Nitschke L. Targeting Human CD22/Siglec-2 with Dimeric Sialosides as Novel Oligosaccharide Mimetics J Med Chem. 2022 Aug 11;65(15):10588-10610._x000D_ 4: Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gökbuget N, O'Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia N Engl J Med. 2016 Aug 25;375(8):740-53._x000D_ 5: Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, Shalabi H, Fountaine TJ, Shern JF, Majzner RG, Stroncek DF, Sabatino M, Feng Y, Dimitrov DS, Zhang L, Nguyen S, Qin H, Dropulic B, Lee DW, Mackall CL. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy Nat Med. 2018 Jan;24(1):20-28._x000D_ 6: Prescher H, Schweizer A, Kuhfeldt E, Nitschke L, Brossmer R. New Human CD22/Siglec-2 Ligands with a Triazole Glycoside Chembiochem. 2017 Jul 4;18(13):1216-1225._x000D_ 7: Hu Y, Zhou Y, Zhang M, Ge W, Li Y, Yang L, Wei G, Han L, Wang H, Yu S, Chen Y, Wang Y, He X, Zhang X, Gao M, Yang J, Li X, Ren J, Huang H. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Clin Cancer Res. 2021 May 15;27(10):2764-2772._x000D_ 8: Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system Nat Rev Immunol. 2007 Apr;7(4):255-66._x000D_ 9: Müller J, Nitschke L. The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease Nat Rev Rheumatol. 2014 Jul;10(7):422-8._x000D_ 10: Pluvinage JV, Haney MS, Smith BAH, Sun J, Iram T, Bonanno L, Li L, Lee DP, Morgens DW, Yang AC, Shuken SR, Gate D, Scott M, Khatri P, Luo J, Bertozzi CR, Bassik MC, Wyss-Coray T. CD22 blockade restores homeostatic microglial phagocytosis in ageing brains Nature. 2019 Apr;568(7751):187-192. _x000D_ _x000D_ Products Related to Recombinant Rhesus Siglec-2/CD22 Protein can be found at Proteins

• Short Description:

  Catalog Number: B2019242 (50 µg)_x000D_ Recombinant Rhesus Siglec-2/CD22 Protein (His Tag) is a laboratory-produced version of the Siglec-2 protein, also known as CD22. It is a member of the Siglecs family, expressed on B cells, and plays a role in B cell activation. This product has been used as a molecular tool for various biochemical applications. It has also been used in a wide array of other chemical and immunological applications. Custom bulk amounts of this product are available upon request._x000D_ _x000D_

• Weight:

  0.15

• Length:

  2

• Width:

  0.5

• Height :

  0.5

• CAS Number:

  9000-83-3